Table 4 Original and post-quality control sequence information in prostate cancer tissue and prostate cancer hyperplasia tissue
Sample name | Number of original sequences (n) | Number of pure sequences (n) | Pure sequence ratio (%) | Q30 (%) |
|---|---|---|---|---|
Ca2 | 12,231,830 | 11,827,333 | 96.69% | 94.64% |
Ca4 | 15,529,734 | 14,950,214 | 96.27% | 97.08% |
Ca5 | 13,979,225 | 13,475,826 | 96.40% | 96.33% |
Ca14 | 11,507,052 | 10,772,859 | 93.62% | 96.09% |
N7 | 14,999,205 | 14,448,964 | 96.33% | 96.80% |
N11 | 18,063,727 | 17,452,607 | 96.62% | 97.23% |
N15 | 14,306,038 | 13,662,588 | 95.50% | 95.72% |
N16 | 13,362,300 | 12,693,394 | 94.99% | 96.68% |